Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
02/2010
02/09/2010CA2431079C Method and composition for the treatment of diabetic neuropathy
02/09/2010CA2410647C Substituted phenylpropanoic acid derivatives
02/09/2010CA2389688C A method of microencapsulation
02/09/2010CA2386297C Bicyclic amino acids as pharmaceutical agents
02/09/2010CA2378431C Peptides that lower blood glucose levels
02/09/2010CA2334222C Insulin supplemented infant formula
02/09/2010CA2287469C Interactive system for presenting and eliminating substances
02/09/2010CA2286614C Plant extracts for the treatment of increased bone resorption
02/09/2010CA2274201C Di-or triaza-spiro[4,5]decane derivatives
02/09/2010CA2150933C Glaucoma treatment
02/04/2010WO2010014889A2 Nitro fatty acids as regiomers and related mimetics
02/04/2010WO2010014771A1 Romazarit for treating metabolic diseases
02/04/2010WO2010014613A2 Treating various disorders using trkb agonists
02/04/2010WO2010013978A2 Composition for prevention or treatment of hyperlipidemia, fatty liver or obesity
02/04/2010WO2010013849A1 Gpr119 agonist
02/04/2010WO2010013798A1 Therapeutic or prophylactic agent for diabetes, obesity, dyslipidemia or metabolic syndrome comprising benzylamine derivative or pharmaceutically acceptable acid addition salt thereof
02/04/2010WO2010013769A1 Crystal of thiazolidinedione compound, and process for production thereof
02/04/2010WO2010013768A1 Crystal of thiazolidinedione compound, and process for production thereof
02/04/2010WO2010013762A1 Metastin derivative and use thereof
02/04/2010WO2010013595A1 (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative
02/04/2010WO2010013494A1 Pharmaceutical composition comprising botulinum neurotoxin preparation incapable of being synaptically transported, and use thereof
02/04/2010WO2010013161A1 Fluorinated heteroaryls
02/04/2010WO2010012964A2 Thiophene-2-carboxamide derivatives, preparation thereof and therapeutic use thereof
02/04/2010WO2010012650A1 Compounds for the treatment of metabolic diseases
02/04/2010WO2010012495A1 Active immunisation against gip
02/04/2010WO2010012434A1 Compositions containing berberine and/or analogues thereof or extracts containing it, for the prevention and treatment of alterations of the lipid and carbohydrate balance
02/04/2010WO2010012153A1 Phlorizin derivatives and their preparation and application
02/04/2010WO2009153569A3 Cb1 receptor modulators
02/04/2010WO2009149258A3 Crystalline form of 6-[(4s)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
02/04/2010US20100029919 Pyrazole derivative, medicinal composition containing the same, medicinal use thereof and intermediate in producing the same
02/04/2010US20100029768 Compositions and Methods For Promoting Fat Loss
02/04/2010US20100029766 Blends Comprising a Substituted Fatty Acid or a Derivative Thereof
02/04/2010US20100029761 Novel compounds, pharmaceutical compositions containing same, and methods of use for same
02/04/2010US20100029760 Obesity and Metabolic Syndrome Treatment with Tanshinone Derivatives Which Increase Metabolic Activity
02/04/2010US20100029757 Use of xanthohumol and/or isoxanthohumol as an agent for preventing and/or combating liver diseases
02/04/2010US20100029744 Methods for Alzheimer's Disease Treatment and Cognitive Enhancement
02/04/2010US20100029736 2-substituted proline bis-amide orexin receptor antagonists
02/04/2010US20100029727 1, 3, 4 -oxadiazole derivatives as dgat1 inhibitors
02/04/2010US20100029724 Screening method
02/04/2010US20100029722 Organic compounds
02/04/2010US20100029721 Pharmaceutical Formulation Comprising Metformin and Repaglinide
02/04/2010US20100029718 Organic compounds
02/04/2010US20100029710 COMPOUNDS HAVING BOTH ANGIOTENSIN II RECEPTOR ANTAGONISM AND PPARy ACTIVATING ACTIVITIES
02/04/2010US20100029697 Substituted pyrido[3,2-e][1,2,4]triazolo[4,3-c]pyrimidine derivatives as cannabinoid-1 receptor modulators
02/04/2010US20100029688 Bipiperidinyl compounds, compositions containing such compounds and methods of treatment
02/04/2010US20100029675 Pyrimidine-2, 4-diamine JAK2 Kinase inhibiting anti-inflammation use
02/04/2010US20100029639 Ion channel modulating compounds and uses thereof
02/04/2010US20100029631 Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient
02/04/2010US20100029622 Microemulsions
02/04/2010US20100029616 Urotensin ii receptor antagonists
02/04/2010US20100029607 Substituted Piperazines as CB1 Antagonists
02/04/2010US20100029589 4,5-dihydro-oxazol-2yl derivatives
02/04/2010US20100029581 Nutritional supplement
02/04/2010US20100029554 Composition and Methods for Treatment of Congestive Heart Failure
02/04/2010US20100029548 Glycoproteins produced in plants and methods of their use
02/04/2010US20100028905 Characterization of grp94-ligand interactions and purification, screening, and therapeutic methods relating thereto
02/04/2010US20100028464 Use of saffron and/or safranal and/or crocin and/or picrocrocin and/or derivatives thereof as a sateity agent for treatment of obesity
02/04/2010US20100028440 Drying of drug-containing particles
02/04/2010US20100028429 Salts of potassium atp channel openers and uses thereof
02/04/2010US20100028417 Use of substituted glycerin derivatives for producing a pharmaceutical preparation
02/04/2010US20100028367 Sgp130/fc dimers
02/04/2010US20100028349 activates FGF receptors, regulates the growth and differentiation of cells within the liver, regulates other cell types following secretion from the liver, plays a role in liver chemotaxis, has an oncogenic activity, or serves as an antigen for generating antibodies; treating diabetes or obesity
02/04/2010US20100028345 Il-17 receptor a antigen binding proteins
02/04/2010US20100028326 Diagnosis of hyperinsulinemia and type ii diabetes and protection against same based on proteins differentially expressed in serum
02/04/2010US20100028307 Pluripotent stem cell differentiation
02/04/2010US20100028301 IMIDAZO[4,5-c]PYRIDINE COMPOUNDS AND METHODS OF ANTIVIRAL TREATMENT
02/04/2010US20100028292 Amphiphilic Polymer-Protein Conjugates and Methods of Use Thereof
02/04/2010US20100028257 Pharmaceutical compounds
02/04/2010US20100026235 Charging Control in an Electric Vehicle
02/04/2010CA2733077A1 Composition for prophylaxis or treatment of hyperlipidemia, fatty liver or obesity
02/04/2010CA2732266A1 Treating various disorders using trkb agonists
02/04/2010CA2731378A1 Therapeutic or prophylactic agent for diabetes, obesity, dyslipidemia or metabolic syndrome, comprising benzylamine derivative or pharmaceutically acceptable acid addition salt thereof
02/04/2010CA2731358A1 5/5-or 5/6-membered condensed ring cycloalkylamine derivative
02/04/2010CA2729581A1 Fluorinated heteroaryls
02/03/2010EP2149563A1 Novel pyrimidine compound having dibenzylamine structure, and medicine comprising the compound
02/03/2010EP2149562A1 method of preparing (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride hemihydrate
02/03/2010EP2149550A1 Nitrogen-containing five-membered heterocyclic compound
02/03/2010EP2149377A1 Compositions containing berberine and/or analogues thereof or extracts containing it, for the prevention and treatment of alterations of the lipid and carbohydrate balance
02/03/2010EP2149369A1 Instant oral formulations, gelling at room temperature, useful to treat physical wasting and the depressive syndrome associated with cachexia, anorexia, metabolic disorders, endocrine disorders and dysphagia
02/03/2010EP2148878A1 Novel heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
02/03/2010EP2148870A1 Pyrimidinone derivatives and methods of use thereof
02/03/2010EP2148867A1 Deuterated morpholinyl compounds
02/03/2010EP2148862A1 Dihydroquinone and dihydronaphthridine inhibitors of jnk
02/03/2010EP2148679A1 Tetrahydropyrido[4,3-d]pyrimidinone derivatives and methods of use thereof
02/03/2010EP1730147B1 Substituted 1,4,8-triazaspiro[4,5]decan-2-on compounds for use in the treatment of obesity
02/03/2010EP1511742B1 Kinase inhibitors
02/03/2010EP1351679B1 Method and composition for the treatment of diabetic neuropathy
02/03/2010CN201393824Y Multifunctional healthcare pillow
02/03/2010CN101638437A Growth hormone fusion protein
02/03/2010CN100586444C Method of processing ginseng for medicinal use and composition
02/03/2010CN100586425C Cinnamon poria capsule and its preparation process
02/02/2010US7655763 Neutralizing antibodies against GDF-8 and uses therefor
02/02/2010US7655760 Antibodies to the polypeptide hormone phosphatonin
02/02/2010US7655694 Phytoestrogenic isoflavone compositions, their preparation and use thereof for protection against and treatment of radiation injury
02/02/2010US7655690 1-sulfonylindole derivatives, their preparation and their use as 5-HT6 ligands
02/02/2010US7655688 Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
02/02/2010US7655663 (2S)-4,4-difluoro-1-(2-{[1-(2-pyrazinyl)piperidin-4-yl]amino}acetyl)-2-pyrrolidine carbonitrile; enzyme inhibitors; diabetes
02/02/2010US7655633 Beta-D-Glucopyranosyloxy)-3-(3-fluoro-4-methylbenzyl)-4,6-dimethylpyridine; sodium glucose co-transporter 2 (SGLT2) inhibitors; excellent hypoglycemic effect by excreting excess glucose into the urine through preventing the reabsorption of glucose at the kidney; antidiabetic agents; hyperglycemia
02/02/2010US7655632 prevention or treatment of disease associated with hyperglycemia: diabetes, impaired glucose tolerance, impaired fasting glycemia, diabetic complications or obesity; e.g. 4-[(4-{3-[1-carbamoyl-1-(methyl)-ethylcarbamoyl]propyl}-2-methylphenyl)methyl]-3-( beta -D-glucopyranosyloxy)-5-isopropyl-1H-pyrazole
02/02/2010US7655226 Treatment of Pompe's disease
1 ... 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 ... 1298